Snapshot from Aug 13, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / ProMIS PMN310 Phase 1b Webinar
Tech clinical trial update

ProMIS PMN310 Phase 1b Webinar

Analysis based on 6 articles · First reported Jul 27, 2026 · Last updated Jul 27, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The webinar may provide early signals on PMN310's safety and biomarker effects, influencing investor sentiment. Positive data could boost ProMIS stock, while negative results may dampen prospects.

Biotechnology Pharmaceuticals
Event Summary

ProMIS Neurosciences Inc. announced it will host a webinar on July 28, 2026, to discuss six-month blinded interim data from the PRECISE-AD Phase 1b trial of PMN310 in early Alzheimer's disease. The webinar will feature KOLs Dr. Will Mantyh and Dr. Michael Weiner, along with CEO Neil Warma and CMO Dr. Larry Altstiel. The analysis will focus on blinded aggregate safety data and biomarker trends. PMN310 is a monoclonal antibody designed to selectively target toxic amyloid-beta oligomers, potentially reducing ARIA risks. The trial enrolled 144 participants across three dosing cohorts.

Key Actions
80 United States — Food and Drug Administration granted Fast Track Designation ProMIS Neurosciences
60 ProMIS Neurosciences announced interim data timeline
Entities Involved
stock
ProMIS Neurosciences
ProMIS is hosting the webinar to discuss its lead candidate PMN310; the event is central to its clinical development.
Importance 100.0 Sentiment 10.0
per
Neil Warma
CEO Neil Warma will speak at the webinar, representing company leadership.
Importance 60.0 Sentiment 5.0
per
Larry Altstiel
CMO Dr. Larry Altstiel will present clinical data at the webinar.
Importance 50.0 Sentiment 5.0
per
Will Mantyh
KOL Dr. Will Mantyh will provide expert commentary on the trial data.
Importance 40.0 Sentiment 0.0
per
Michael Weiner
KOL Dr. Michael Weiner will provide expert commentary on the trial data.
Importance 40.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
FDA granted Fast Track Designation to PMN310 in July 2025.
Importance 30.0 Sentiment 0.0
govactor
United States — National Institutes of Health
Dr. Mantyh is PI of an NIH grant, but not directly involved in this event.
Importance 10.0 Sentiment 0.0
ngo
Alzheimer s Association
Dr. Weiner received awards from the Alzheimer s Association.
Importance 10.0 Sentiment 0.0
ngo
American Academy of Neurology
Dr. Weiner received the Potamkin Prize from AAN.
Importance 5.0 Sentiment 0.0
oth
Toulouse III - Paul Sabatier University
Dr. Weiner received an honorary degree from Toulouse III - Paul Sabatier University.
Importance 5.0 Sentiment 0.0
priv
Vaicro
Dr. Weiner is CEO of Vaicro, an AI voice company.
Importance 5.0 Sentiment 0.0
priv
LifeSci Communications
LifeSci Communications is the media contact for the announcement.
Importance 5.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ United States — National Institutes of Health
United States — Food and Drug Administration related ↔ Alzheimer s Association
United States — National Institutes of Health related ↔ Alzheimer s Association
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.